"The best part is that our combined drug candidate was so much more effective than one of the most powerful cancer drugs on the market," said Jonathan Sessler

"We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's leukemia signs disappeared overnight," said Professor Ben-Neriah.

"Our findings could provide an opportunity to improve future engineering of CAR T cells against tumors...."

"We believe we've found an approach that is most relevant to humans, in that our models of gene dysfunction mimic the etiology of Parkinson's disease rather than its pathology....

This opens up new treatment strategies for diseases that involve impairment of the body's ability to break down...

The breakthrough provides a better understanding of the individualized nature of the disease says the research team. 

Lower prices negotiated and provided as part of our ongoing mission to make medicines more accessible. 
 

2018 has been a good year for new cancer treatments says the U.S. AACR. 
 

Kisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US.

The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.

The new preventive medicine for migraine Aimovig (erenumab) has been approved by the EMA. Read more...
 

7 need-to-knows about migraine as well as some updates on the latest treatment developments

The dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

The latest approval renders the previous 'temporary approval' a full approval, without further results needed.

The 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

The FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.

Researchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

The study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment. 

A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.

New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.

The first-ever preventative treatment for migraine in adults, Aimovig (erenumab-aooe) is now approved by the Food and Drug Administration.

Lucemyra (lofexidine hydrochloride), now approved by the Food and Drug Administration, may offer relief (and new hope) for patients experiencing withdrawal symptoms from opioid dependence.

This will provide a much-needed alternative therapy for a debilitating disease with limited treatment options. 



Moderately to severely active ulcerative colitis can now be treated with Xeljanz (tofacitinib), following the expanded approval by the Food and Drug Administration (FDA). This will provide a much-needed alternative therapy for a debilitating disease with limited treatment options.

"We currently test for liver cancer using ultrasound and a blood protein marker called alpha fetoprotein," says John Kisiel, M.D., a gastroenterologist at Mayo Clinic. "Unfortunately, these tests are not very sensitive for curable stage liver cancers, and most patients who need this testing do not have it easily available or [are] not able to receive it often enough to be effective." The new advance by the team opens the door to further development of a DNA test.